AU2016281641B2 - Novel PD-1 immune modulating agents - Google Patents

Novel PD-1 immune modulating agents Download PDF

Info

Publication number
AU2016281641B2
AU2016281641B2 AU2016281641A AU2016281641A AU2016281641B2 AU 2016281641 B2 AU2016281641 B2 AU 2016281641B2 AU 2016281641 A AU2016281641 A AU 2016281641A AU 2016281641 A AU2016281641 A AU 2016281641A AU 2016281641 B2 AU2016281641 B2 AU 2016281641B2
Authority
AU
Australia
Prior art keywords
gly
ser
thr
ala
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016281641A
Other languages
English (en)
Other versions
AU2016281641A1 (en
Inventor
Renier J. Brentjens
Hollie Jaine JACKSON
Cheng Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Eureka Therapeutics Inc
Original Assignee
Memorial Sloan Kettering Cancer Center
Eureka Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center, Eureka Therapeutics Inc filed Critical Memorial Sloan Kettering Cancer Center
Publication of AU2016281641A1 publication Critical patent/AU2016281641A1/en
Application granted granted Critical
Publication of AU2016281641B2 publication Critical patent/AU2016281641B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/418—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2016281641A 2015-06-23 2016-06-23 Novel PD-1 immune modulating agents Active AU2016281641B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562183297P 2015-06-23 2015-06-23
US62/183,297 2015-06-23
US201562266398P 2015-12-11 2015-12-11
US62/266,398 2015-12-11
PCT/US2016/039015 WO2016210129A1 (en) 2015-06-23 2016-06-23 Novel pd-1 immune modulating agents

Publications (2)

Publication Number Publication Date
AU2016281641A1 AU2016281641A1 (en) 2018-02-08
AU2016281641B2 true AU2016281641B2 (en) 2022-01-20

Family

ID=56373127

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016281641A Active AU2016281641B2 (en) 2015-06-23 2016-06-23 Novel PD-1 immune modulating agents

Country Status (11)

Country Link
US (1) US11136392B2 (enExample)
EP (1) EP3313883B1 (enExample)
JP (2) JP6974311B2 (enExample)
KR (1) KR20180019725A (enExample)
CN (2) CN108337890B (enExample)
AU (1) AU2016281641B2 (enExample)
CA (1) CA3006224A1 (enExample)
HK (1) HK1254803A1 (enExample)
IL (1) IL256463A (enExample)
TW (1) TWI773647B (enExample)
WO (1) WO2016210129A1 (enExample)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017014822A (es) 2015-05-18 2018-04-30 Tcr2 Therapeutics Inc Composiciones y métodos para la reprogramación del tcr con proteínas de fusión.
FI3909972T3 (fi) 2015-06-19 2024-05-03 Sebastian Kobold Pd1-cd28-fuusioproteiineja ja niiden käyttö lääkkeessä
EP3313883B1 (en) * 2015-06-23 2023-12-06 Memorial Sloan Kettering Cancer Center Novel pd-1 immune modulating agents
CN114591433A (zh) 2015-07-13 2022-06-07 西托姆克斯治疗公司 抗pd-1抗体、可活化抗pd-1抗体及其使用方法
CN114605548A (zh) 2015-09-01 2022-06-10 艾吉纳斯公司 抗-pd-1抗体及其使用方法
HK1251158A1 (zh) 2015-09-29 2019-01-25 细胞基因公司 Pd-1结合蛋白及其使用方法
SMT202100506T1 (it) 2015-10-02 2021-11-12 Hoffmann La Roche Anticorpi bispecifici specifici per pd1 e tim3
SMT202200118T1 (it) 2015-11-03 2022-05-12 Janssen Biotech Inc Anticorpi che legano specificamente pd-1 e loro usi
WO2017133175A1 (en) * 2016-02-04 2017-08-10 Nanjing Legend Biotech Co., Ltd. Engineered mammalian cells for cancer therapy
US11549099B2 (en) 2016-03-23 2023-01-10 Novartis Ag Cell secreted minibodies and uses thereof
WO2017180587A2 (en) 2016-04-11 2017-10-19 Obsidian Therapeutics, Inc. Regulated biocircuit systems
AU2017329024A1 (en) 2016-09-19 2019-03-21 Celgene Corporation Methods of treating immune disorders using pd-1 binding proteins
WO2018053401A1 (en) 2016-09-19 2018-03-22 Celgene Corporation Methods of treating vitiligo using pd-1 binding proteins
EP3544996A2 (en) 2016-11-22 2019-10-02 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
CN118634323A (zh) 2016-12-07 2024-09-13 艾吉纳斯公司 抗体和其使用方法
EP3557671A4 (en) * 2016-12-19 2020-08-19 Showa Denko K.K. PROCEDURE FOR OPERATING A REDOX FLOW BATTERY
EP3596108A4 (en) 2017-03-15 2020-12-23 Pandion Operations, Inc. TARGETED IMMUNOTOLERANCE
KR20190121816A (ko) 2017-04-03 2019-10-28 에프. 호프만-라 로슈 아게 항-pd-1 항체와 돌연변이 il-2 또는 il-15의 면역접합체
PL3606955T3 (pl) 2017-04-05 2025-02-24 F. Hoffmann-La Roche Ag Przeciwciała dwuswoiste swoiście wiążące się z PD1 i LAG3
HUE060019T2 (hu) * 2017-04-05 2023-01-28 Hoffmann La Roche Anti-LAG3 antitestek
EP3612222A4 (en) * 2017-04-19 2020-12-23 University of Southern California COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER
CN110741016A (zh) 2017-04-26 2020-01-31 优瑞科生物技术公司 嵌合抗体/t-细胞受体构筑体及其用途
WO2018204303A1 (en) * 2017-05-01 2018-11-08 The Children's Medical Center Coporation Methods and compositions relating to anti-pd1 antibody reagents
AU2018273914A1 (en) 2017-05-24 2019-11-14 Pandion Operations, Inc. Targeted immunotolerance
TW202542197A (zh) * 2017-07-06 2025-11-01 荷蘭商米樂斯股份有限公司 藉由細胞表現之調控生物活性的抗體
US11884934B2 (en) * 2017-07-21 2024-01-30 Washington University Methods and compositions for T cell activation
KR102845789B1 (ko) 2017-11-01 2025-08-14 주노 쎄러퓨티크스 인코퍼레이티드 B 세포 성숙 항원에 특이적인 키메라 항원 수용체 및 암호화 폴리뉴클레오타이드
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
KR20200128014A (ko) * 2018-01-31 2020-11-11 셀진 코포레이션 입양 세포 요법 및 체크포인트 억제제를 이용한 병용 요법
WO2019161133A1 (en) 2018-02-15 2019-08-22 Memorial Sloan Kettering Cancer Center Foxp3 targeting agent compositions and methods of use for adoptive cell therapy
TWI708787B (zh) 2018-03-02 2020-11-01 美商美國禮來大藥廠 Pd-1促效劑抗體及其用途
KR20210011919A (ko) 2018-04-17 2021-02-02 셀덱스 쎄라퓨틱스, 인크. 항-cd27 항체 및 항-pd-l1 항체 및 이중특이적 작제물
US20210301024A1 (en) * 2018-07-04 2021-09-30 Cytoimmune Therapeutics, Inc. Compositions and methods for immunotherapy targeting flt3, pd-1, and/or pd-l1
WO2020097403A1 (en) 2018-11-08 2020-05-14 Juno Therapeutics, Inc. Methods and combinations for treatment and t cell modulation
CN111320690B (zh) * 2018-12-17 2022-04-05 程联胜 一种抗人Tim3单克隆抗体及其应用
CN111748580B (zh) * 2019-03-28 2022-09-13 百奥泰生物制药股份有限公司 一种检测免疫检查点抗体活性的方法
CN111892655B (zh) * 2019-05-06 2022-10-28 四川大学 抗pd-1纳米抗体的筛选及应用
TW202110885A (zh) 2019-05-20 2021-03-16 美商潘迪恩治療公司 靶向ＭＡｄＣＡＭ之免疫耐受性
AU2020290971A1 (en) * 2019-06-14 2021-12-23 Dana-Farber Cancer Institute, Inc. Antibodies against PD-1 and methods of use thereof
EP3998081A4 (en) 2019-07-05 2023-07-12 Ono Pharmaceutical Co., Ltd. TREATMENT OF BLOOD CANCER WITH PD-1/CD3 DUAL SPECIFICITY PROTEIN
WO2021011480A1 (en) * 2019-07-12 2021-01-21 The Research Foundation For The State University Of New York Compositions and methods to block and bind cxcr4 to modulate cellular function
JP7771749B2 (ja) 2019-08-08 2025-11-18 小野薬品工業株式会社 二重特異性タンパク質
WO2021034689A1 (en) * 2019-08-16 2021-02-25 H. Lee Moffitt Cancer Center And Research Institute Inc. Anti-cd83 chimeric antigen receptor expressing t regulatory cells
CN112852740A (zh) * 2019-11-27 2021-05-28 深圳市菲鹏生物治疗股份有限公司 Car-t细胞和检测方法
TWI866327B (zh) 2019-12-23 2024-12-11 南韓商Ｌｇ化學股份有限公司 抗ｌｉｌｒｂ１抗體和彼之用途
WO2021168079A1 (en) 2020-02-21 2021-08-26 Pandion Operations, Inc. Tissue targeted immunotolerance with a cd39 effector
PH12022553181A1 (en) 2020-05-26 2024-03-04 Boehringer Ingelheim Int Anti-pd-1 antibodies
CN114437229B (zh) * 2020-11-01 2024-03-12 复旦大学 携带pd-1単链抗体且靶向egfr抗原的car t免疫细胞的制备及其用途
CN112812174A (zh) * 2021-01-15 2021-05-18 新乡学院 猪pd-l14qn-af表位多肽及其应用
CN115521378B (zh) * 2021-07-23 2023-12-22 南京吉盛澳玛生物医药有限公司 Pd-l1抗体及其用途
WO2024182754A2 (en) * 2023-03-02 2024-09-06 Fred Hutchinson Cancer Center Anti-pd-1 chimeric antigen receptor t cells and therapeutic uses thereof
WO2025059162A1 (en) 2023-09-11 2025-03-20 Dana-Farber Cancer Institute, Inc. Car-engager containing il-2 variants to enhance the functionality of car t cells
WO2025085538A1 (en) * 2023-10-17 2025-04-24 Lanier Biotherapeutics, Inc. Alarmin binding molecules and treatment of cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8354509B2 (en) * 2007-06-18 2013-01-15 Msd Oss B.V. Antibodies to human programmed death receptor PD-1

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4834976A (en) * 1986-07-03 1989-05-30 Genetic Systems Corporation Monoclonal antibodies to pseudomonas aeruginosa flagella
CN1753912B (zh) * 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
ES2720160T3 (es) * 2005-05-09 2019-07-18 Ono Pharmaceutical Co Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas
RU2769948C2 (ru) * 2007-04-03 2022-04-11 Эмджен Рисерч (Мьюник) Гмбх CD3-Эпсилон-связывающий домен с межвидовой специфичностью
CA2842368A1 (en) * 2011-07-29 2013-02-07 The Trustees Of The University Of Pennsylvania Switch costimulatory receptors
WO2014116846A2 (en) 2013-01-23 2014-07-31 Abbvie, Inc. Methods and compositions for modulating an immune response
CN103965363B (zh) * 2013-02-06 2021-01-15 上海白泽生物科技有限公司 与pd-1和vegf高效结合的融合蛋白、其编码序列及用途
EP2961831B1 (en) * 2013-02-26 2020-06-10 Memorial Sloan Kettering Cancer Center Compositions and methods for immunotherapy
CN103242448B (zh) * 2013-05-27 2015-01-14 郑州大学 一种全人源化抗pd-1单克隆抗体及其制备方法和应用
CN104558177B (zh) * 2013-10-25 2020-02-18 苏州思坦维生物技术股份有限公司 拮抗抑制程序性死亡受体pd-1与其配体结合的单克隆抗体及其编码序列与用途
SG11201704550XA (en) * 2014-12-05 2017-07-28 Memorial Sloan Kettering Cancer Center Chimeric antigen receptors targeting fc receptor-like 5 and uses thereof
CN104479020B (zh) * 2014-12-26 2019-08-02 上海复宏汉霖生物技术股份有限公司 一种抗pd-1人源抗体
EP3297673A4 (en) * 2015-05-22 2019-05-08 Memorial Sloan-Kettering Cancer Center FOR A PRAME-PEPTIDE SPECIFIC T-CELL RECEPTOR-SIMILAR ANTIBODIES
EP3313883B1 (en) * 2015-06-23 2023-12-06 Memorial Sloan Kettering Cancer Center Novel pd-1 immune modulating agents
BR112018011336A2 (pt) * 2015-12-04 2018-12-04 Memorial Sloan-Kettering Cancer Center anticorpo anti-fcrl5 isolado ou um fragmento de ligação ao antígeno do mesmo, anticorpo scfv anti-fcrl5 isolado, anticorpo isolado ou porção de ligação ao antígeno do mesmo, composição, imunoconjugado, molécula biespecífica, ácido nucleico isolado, vetor de expressão, célula hospedeira, método para detectar fcrl5 em uma célula ou tecido inteiro, método para tratar câncer em um indivíduo, uso do anticorpo ou fragmento de ligação ao antígeno do mesmo, kit para tratar câncer
WO2017124001A2 (en) * 2016-01-14 2017-07-20 Memorial Sloan-Kettering Cancer Center T cell receptor-like antibodies specific for foxp3-derived peptides
HRP20211703T1 (hr) * 2016-11-02 2022-02-04 Jounce Therapeutics, Inc. Protutijela protiv pd-1 i njihova upotreba
CN111433354A (zh) * 2017-09-26 2020-07-17 朗沃德大学 作为免疫疗法的pd1特异性嵌合抗原受体

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8354509B2 (en) * 2007-06-18 2013-01-15 Msd Oss B.V. Antibodies to human programmed death receptor PD-1

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JOHN, L.B. et al., ‘Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells’, CLINICAL CANCER RESEARCH. 2013, Vol. 19, No. 20, pages 5636-5646 *

Also Published As

Publication number Publication date
AU2016281641A1 (en) 2018-02-08
JP2021177768A (ja) 2021-11-18
EP3313883A1 (en) 2018-05-02
CN114133448A (zh) 2022-03-04
CA3006224A1 (en) 2016-12-29
CN108337890B (zh) 2021-10-15
TW201718648A (zh) 2017-06-01
KR20180019725A (ko) 2018-02-26
WO2016210129A1 (en) 2016-12-29
HK1254803A1 (zh) 2019-07-26
JP2018518540A (ja) 2018-07-12
CN108337890A (zh) 2018-07-27
US20180127502A1 (en) 2018-05-10
EP3313883B1 (en) 2023-12-06
US11136392B2 (en) 2021-10-05
TWI773647B (zh) 2022-08-11
IL256463A (en) 2018-02-28
JP6974311B2 (ja) 2021-12-01

Similar Documents

Publication Publication Date Title
AU2016281641B2 (en) Novel PD-1 immune modulating agents
KR102340832B1 (ko) 항 pd-1 항체 및 그의 용도
KR102710122B1 (ko) 항-ctla-4 항체 및 이의 용도
CN108368178B (zh) 抗lag3抗体及其用途
CN107921127B (zh) 对于prame肽具有特异性的t细胞受体样抗体
KR102838340B1 (ko) 다중-특이적 항체 및 이들의 제조 및 사용 방법
CN107847596B (zh) 抗ror1抗体
KR101418606B1 (ko) Ｈｅｒ-３ 지향 항체 및 그 용도
KR20180132751A (ko) Bcma 결합 분자 및 그의 사용 방법
CN112262155A (zh) 结合cd39的抗体及其用途
KR20180089497A (ko) Fc 수용체-유사 5를 표적화하는 항체 및 사용 방법
HUE035865T2 (en) Combination of dr5 agonist and anti-pd-1 antagonist and methods of use
KR20180133399A (ko) 인간 폴리오바이러스 수용체(ｐｖｒ)에 특이적인 항체
KR20140033029A (ko) 에이치엘에이 에이2에 의해 제공된 더블유티1 펩타이드에 특이적인 티 세포 수용체 유사 항체
EP3625260A1 (en) Treatment of cancer with anti-gitr agonist antibodies
KR20080090393A (ko) 생물학적 물질 및 이의 용도
JP2024541175A (ja) Ｈｅｒｖ－ｋ抗体治療法
CN114685653B (zh) 抗新冠病毒受体结合区域表位中和抗体及其应用
CN112839963B (zh) 新型癌症免疫治疗抗体组合物
RU2804490C2 (ru) Новые композиции антител для иммунотерапии рака
KR20150131219A (ko) Ｗｔ－１－양성 질병 치료용 조합/보조제 요법
RU2811477C2 (ru) Мультиспецифические антитела и способы их получения и применения
RU2774158C2 (ru) Антитела, направленные против fc-рецептор-подобного белка 5, и способы их применения
HK40047112B (en) Novel cancer immunotherapy antibody compositions
CN116018351A (zh) 靶向cd123的抗体、嵌合抗原受体及其用途

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)